Author Archives: Somi Igbene

Ianalumab, an Antibody, Eases Sjögren’s Symptoms at High Dose in Trial

Ianalumab (VAY736), an investigational antibody to treat Sjögren’s syndrome, at high dose was well-tolerated by patients using it for one year, and led to reductions in disease activity and significantly greater saliva production, data from a Phase 2b clinical trial show. Findings were shared at the 2021 American College of Rheumatology…

Loss of Smell Linked to Disease Severity

Sensitivity to smell is reduced in people with Sjögren’s syndrome, compared with healthy controls, and appears to be linked to the severity of the disease, a new study reports. The study, “Olfactory impairment in patients with primary Sjogren’s syndrome and its correlation with organ involvement and immunological abnormalities,”…